Advertisement

Aequus Pharmaceuticals Third Quarter 2022 Earnings: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals (CVE:AQS) Third Quarter 2022 Results

Key Financial Results

  • Revenue: CA$347.9k (down 51% from 3Q 2021).

  • Net loss: CA$500.5k (loss widened by 31% from 3Q 2021).

  • CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 3Q 2021).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aequus Pharmaceuticals' share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Aequus Pharmaceuticals (including 4 which make us uncomfortable).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here